In a nutshell This study compared the safety of two hormonal medications used to treat breast cancer, tamoxifen (Nolvadex) and letrozole (Femara). This study found that tamoxifen was associated with an increased risk of blood clots, while letrozole was associated with an increased risk of angina and heart attacks. Some background Hormone-positive...
Read More
In a nutshell This study will investigate the safety and effectiveness of tiragolumab combined with atezolizumab (Tecentriq) and chemotherapy to treat triple-negative breast cancer (TNBC). The main outcome will be the occurrence of side effects and the objective response rate (ORR). The details Breast cancer (BC) is the most...
Read More
In a nutshell This trial is being carried out to assess the safety and effectiveness of an experimental drug called BCA101 alone and in combination with pembrolizumab (Keytruda) in advanced solid tumors that are EGFR-positive. The main outcomes to be measured are the occurrence of side effects and response to treatment. The details Advanced solid...
Read More
In a nutshell This study was carried to examine the effectiveness of using chest computed tomography (CT) for the screening of osteoporosis (OP) and predicting the risk of fractures (bone breaks) in patients with breast cancer (BC). The authors found that CT can be used for predicting OP and determining the risk of fractures in these...
Read More
In a nutshell The study evaluated whether Breast Cancer Index (BCI) can predict benefits from extended endocrine therapy (EET) in patients with hormone-receptor-positive (HR+) early-stage breast cancer (BC). The authors found that BCI can predict which patients would benefit from 10 years of EET. Some background Endocrine therapy (ET) prevents tumor...
Read More
In a nutshell This study is looking to trial the addition of a new form of vaccine called a neoantigen vaccine in combination with nab–paclitaxel (Abraxane), duvalumab (Imfinzi), and tremelimumab (CP-675,206), in patients with metastatic triple-negative breast cancer (mTNBC). The main outcome that will be measured is survival without the...
Read More
In a nutshell This study was carried out to look at the risk of developing a second cancer in patients with breast cancer (BC) undergoing statin therapy. The authors found that there was little association between statin use and second cancer risk in these patients. Some background BC is one of the most common forms of cancer found in women. With...
Read More
In a nutshell This study compared the effectiveness of breast-conserving surgery (BCS) to mastectomy (breast-removal surgery) after chemotherapy in patients with breast cancer. The authors found that BCS does not result in a lower survival in these patients. Some background BC is one of the most common forms of cancer in women. Standard care...
Read More
In a nutshell This article aimed to examine the effectiveness of an immediate breast reconstruction (IBR) approach using DIEP-flap repair and compared it to the standard treatment of a delayed breast reconstruction (DBR) in women with breast cancer (BC) undergoing mastectomy (breast removal surgery). The authors concluded that IBR should be...
Read More
In a nutshell This article looked at different types of non-drug therapies for the management of menopausal symptoms (MS) such as night sweats and hot flushes in breast cancer (BC) survivors. The authors concluded that cognitive-behavioral therapy (CBT) and hypnosis may offer some benefit for these women. Some background BC is the most common cancer...
Read More
In a nutshell This trial was carried out to analyze whether the length of time without treatment and the length of time without active disease influences the survival of patients with advanced breast cancer (ABC) spread to the bone taking palbociclib (Ibrance) plus hormonal therapy (HT). The authors concluded...
Read More
In a nutshell The study evaluated outcomes of lapatinib (Tykerb), trastuzumab (Herceptin), and aromatase inhibitor (AI) in postmenopausal women with human epidermal growth factor receptor 2-positive (HER2+) and hormone receptor-positive (HR+) metastatic breast cancer (MBC). The authors found that the combination was safe and effective in such...
Read More
